Omeros Return on Tangible Equity 2010-2025 | OMER
Current and historical return on tangible equity values for Omeros (OMER) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Omeros Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-06-30 | $-0.12B | $-0.23B | 62.05% |
| 2025-03-31 | $-0.15B | $-0.21B | 89.94% |
| 2024-12-31 | $-0.16B | $-0.18B | 117.07% |
| 2024-09-30 | $-0.13B | $-0.15B | 142.93% |
| 2024-06-30 | $-0.14B | $-0.13B | 238.30% |
| 2024-03-31 | $-0.12B | $-0.07B | 543.82% |
| 2023-12-31 | $-0.12B | $-0.03B | -1275.68% |
| 2023-09-30 | $0.02B | $-0.01B | 54.05% |
| 2023-06-30 | $0.04B | $0.02B | 141.38% |
| 2023-03-31 | $0.05B | $0.06B | 303.23% |
| 2022-12-31 | $0.05B | $0.09B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.05B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.03B | -280.14% |
| 2022-03-31 | $0.20B | $-0.01B | -160.00% |
| 2021-12-31 | $0.19B | $0.02B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.26B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.25B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.22B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.12B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.09B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.16B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.11B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.14B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.13B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.305B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.741B | 26.94 |
| Boston Scientific (BSX) | United States | $155.895B | 37.18 |
| Stryker (SYK) | United States | $147.123B | 29.95 |
| EssilorLuxottica (ESLOY) | France | $145.891B | 0.00 |
| Medtronic (MDT) | Ireland | $116.772B | 16.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.160B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.031B | 25.15 |
| ResMed (RMD) | United States | $42.217B | 30.19 |
| GE HealthCare Technologies (GEHC) | United States | $33.398B | 15.70 |
| Agilent Technologies (A) | United States | $33.278B | 21.69 |
| Terumo (TRUMY) | Japan | $27.302B | 32.35 |
| Koninklijke Philips (PHG) | Netherlands | $26.423B | 17.48 |
| Insulet (PODD) | United States | $23.078B | 77.32 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.685B | 13.17 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.192B | 0.00 |
| Baxter (BAX) | United States | $12.250B | 9.46 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.714B | 28.33 |
| Lantheus Holdings (LNTH) | United States | $4.023B | 10.88 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.400B | 23.79 |
| Perrigo (PRGO) | Ireland | $3.224B | 8.05 |
| Prestige Consumer Healthcare (PBH) | United States | $3.221B | 14.29 |
| ICU Medical (ICUI) | United States | $3.005B | 20.46 |
| Haemonetics (HAE) | United States | $2.601B | 11.61 |
| LeMaitre Vascular (LMAT) | United States | $2.183B | 46.82 |
| Acuren (TIC) | United States | $2.054B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.918B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.804B | 77.48 |
| AtriCure (ATRC) | United States | $1.776B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.742B | 10.97 |
| Phibro Animal Health (PAHC) | United States | $1.279B | 16.35 |
| AdaptHealth (AHCO) | United States | $1.261B | 17.92 |
| Tilray Brands (TLRY) | Canada | $1.222B | 0.00 |
| Neogen (NEOG) | United States | $1.216B | 19.31 |
| BioLife Solutions (BLFS) | United States | $1.201B | 2508.00 |
| Valneva SE (VALN) | France | $0.952B | 0.00 |
| InMode (INMD) | Israel | $0.898B | 8.31 |
| Kestra Medical Technologies (KMTS) | United States | $0.876B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.622B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.609B | 0.00 |
| SNDL (SNDL) | Canada | $0.589B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.587B | 0.00 |
| ZimVie (ZIMV) | United States | $0.534B | 20.58 |
| Surmodics (SRDX) | United States | $0.516B | 0.00 |
| Evolus (EOLS) | United States | $0.480B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.471B | 16.20 |
| CeriBell (CBLL) | United States | $0.428B | 0.00 |
| Owens & Minor (OMI) | United States | $0.392B | 3.48 |
| Sanuwave Health (SNWV) | United States | $0.354B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.321B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.303B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.297B | 0.00 |
| Brainsway (BWAY) | Israel | $0.283B | 57.65 |
| Viemed Healthcare (VMD) | United States | $0.273B | 20.74 |
| High Tide (HITI) | Canada | $0.273B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.272B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.270B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.231B | 0.00 |
| Cerus (CERS) | United States | $0.230B | 0.00 |
| Quanterix (QTRX) | United States | $0.225B | 0.00 |
| Exagen (XGN) | United States | $0.220B | 0.00 |
| Organigram Global (OGI) | Canada | $0.210B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.209B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.184B | 15.37 |
| FitLife Brands (FTLF) | United States | $0.155B | 19.10 |
| Biote (BTMD) | United States | $0.149B | 4.95 |
| Jushi Holdings (JUSHF) | United States | $0.131B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.17 |
| Quipt Home Medical (QIPT) | United States | $0.092B | 0.00 |
| MacroGenics (MGNX) | United States | $0.091B | 0.00 |
| Jin Medical (ZJYL) | China | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.084B | 0.00 |
| Apyx Medical (APYX) | United States | $0.078B | 0.00 |
| Safety Shot (SHOT) | United States | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.054B | 31.47 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| Veru (VERU) | United States | $0.052B | 0.00 |
| Zynex (ZYXI) | United States | $0.046B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 33.50 |
| Rockwell Medical (RMTI) | United States | $0.040B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 14.82 |
| Trinity Biotech (TRIB) | Ireland | $0.028B | 0.00 |
| Senestech (SNES) | United States | $0.022B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |